CATEGORY: HEART & CIRCULATION
“It’s only moderate. We’ll keep an eye on it.” That’s what most people hear when an echocardiogram (an ultrasound picture of the heart) shows the heart’s main outflow valve stiffening but not yet severely blocked. A trial published this week asked whether watching is really the safer path, and for patients with warning signs the answer leaned no: replacing the valve right away cut the two-year rate of death or heart failure events by about a third, 16.7% versus 23.9%, roughly 7 fewer events for every 100 people treated. The whole difference came from heart failure. Deaths alone were no lower.1
A Valve Like a Door With Rusting Hinges
Aortic stenosis means the valve between the heart and the body’s main artery is narrowing, usually from calcium buildup with age. Think of a door whose hinges are slowly rusting shut. For a while, it still opens enough. The severe stage has long justified replacement. The moderate stage is traditionally watched, with scans every six to twelve months. But moderate doesn’t always feel moderate: nearly every patient in this trial had symptoms, and each had at least one worrying feature, such as early strain on the heart muscle. Researchers enrolled 744 such adults, average age 78, at 74 hospitals in six countries. About four in ten were women, and nearly half were healthy enough to count as low-risk for ordinary valve surgery. Half got TAVR (transcatheter aortic valve replacement), which threads a new valve up through a leg artery and seats it inside the old one, no open surgery involved. The other half were monitored according to guidelines and had replacements later if the narrowing became severe. A random draw, not a doctor’s judgment, made the split.
Fewer Hospital Stays, the Same Number of Deaths
Over two years, 16.7% of the early-replacement group died or had a heart failure event, against 23.9% of the monitored group. Hospital stays for heart failure were cut about in half, 7.4% versus 14.9%. Quality-of-life scores jumped roughly 15 points on a 100-point scale within a month of the procedure, while the monitored group’s scores drifted down. Put another way, treating 14 people early prevented one death or heart failure event. Deaths told a different story: 8.4% with early replacement, 7.3% with monitoring, a wash. The procedure itself looked safe in these patients. Major complications hit 5.9% in the first 30 days, comfortably under the trial’s prespecified safety bar, and there were no deaths or disabling strokes in that window.1
Watchful Waiting Rarely Lasted Long
Here’s the detail that may matter most to anyone told to wait. Monitoring proved temporary for most who tried it. More than a quarter of the surveillance group needed their valve replaced within a year, and 57% within two, the great majority after their narrowing progressed to severe. So the trial’s real comparison was often “replace now” versus “replace in a year or two,” and the question becomes what those months cost. Not survival, on this data. They paid with their well-being: more heart failure hospital visits and lower quality-of-life scores while waiting, which only improved after the surgery. Patients who crossed over did still improve once treated, gaining about 22 points on the same scale within a month of their own procedure.1
Where Earlier Replacement Worked Before, and Where It Didn’t
Aortic stenosis is common in later life, and the question of when to fix it touches a growing number of older adults as valve procedures get safer. The result extends a pattern. In 2025, the EARLY TAVR trial found that people with severe but symptom-free stenosis fared markedly better with prompt replacement than with surveillance, 26.8% versus 45.3% on a combined measure of death, stroke or unplanned heart hospitalization.2 Early intervention isn’t a universal win, though. A smaller test called TAVR UNLOAD looked at people with moderate stenosis and weak hearts, but it did not show clear benefits compared to regular monitoring. The new study included a different group, mostly those with normal heart function, and here the benefits showed up. Two caveats belong beside the numbers. Edwards Lifesciences, maker of the valve used, funded the study, and this valve isn’t yet approved for moderate stenosis. Follow-up is planned out to ten years, which should show whether the advantage grows, holds or fades.
Key Takeaways
- Early valve replacement lowered the combined two-year rate of death or heart failure events, 16.7% versus 23.9%, driven by far fewer heart failure hospitalizations and better quality of life.
- Deaths alone didn’t differ at two years, so the gain so far is avoided heart failure trouble, not longer survival.
- Watchful waiting was often brief anyway: 57% of monitored patients needed the valve replaced within two years.
- The valve’s manufacturer funded the trial, and using it this early isn’t an approved indication yet.
References
- Généreux P, et al. TAVR in Patients with Moderate Aortic Stenosis with At-Risk Features. New England Journal of Medicine. 2026; DOI 10.1056/NEJMoa2607326. link
- Généreux P, Schwartz A, Oldemeyer JB, et al. Transcatheter Aortic-Valve Replacement for Asymptomatic Severe Aortic Stenosis. New England Journal of Medicine. 2025;392(3):217–227. link
- Van Mieghem NM, Elmariah S, Spitzer E, et al. Transcatheter Aortic Valve Replacement in Patients With Systolic Heart Failure and Moderate Aortic Stenosis: TAVR UNLOAD. Journal of the American College of Cardiology. 2025;85(9):878–890. link